不可不知抗生素的9大误区

2017-06-19 佚名 临床药师网

在生活中想必我们每个人多多少少都服用过抗生素,有些朋友甚至会把抗生素当做“神药”,不管什么病,首先就服用几粒抗生素。但随着医学知识的慢慢普及,有些人对抗生素唯恐避之而不及,不管病的多严重,坚决不用抗生素。这两种极端现象的存在,足以说明大众对抗生素产生了很大误解。抗生素并不是什么“神药”,也并非一点都不能碰,只要我们消除掉平时用药的一些误区,抗生素也能被我们很好的利用。01误区一:感冒就用抗生素病毒

在生活中想必我们每个人多多少少都服用过抗生素,有些朋友甚至会把抗生素当做“神药”,不管什么病,首先就服用几粒抗生素。但随着医学知识的慢慢普及,有些人对抗生素唯恐避之而不及,不管病的多严重,坚决不用抗生素。

这两种极端现象的存在,足以说明大众对抗生素产生了很大误解。抗生素并不是什么“神药”,也并非一点都不能碰,只要我们消除掉平时用药的一些误区,抗生素也能被我们很好的利用。

01

误区一:感冒就用抗生素

病毒或者细菌都可以引起感冒。病毒引起的感冒属于病毒性感冒,细菌引起的感冒属于细菌性感冒。抗生素只对细菌性感冒有用。

其实,很多感冒都属于病毒性感冒。严格意义上讲,对病毒性感冒并没有什么有效的药物,只是对症治疗,而不需要使用抗生素。大家可能都有过这种经历,感冒以后习惯性在药店买一些感冒药,同时加一点抗生素来使用。实际上抗生素在这个时候是没有用处的,是浪费也是滥用。

02

误区二:发烧就用抗生素

抗生素仅适用于由细菌和部分其他微生物引起的炎症发热,对病毒性感冒、麻疹、腮腺炎、伤风、流感等患者给予抗生素治疗有害无益。咽喉炎、上呼吸道感染者多为病毒引起,抗生素无效。

此外,就算是细菌感染引起的发热也有多种不同的类型,不能盲目地就使用头孢菌素等抗生素。比如结核引起的发热,如果盲目使用抗生素而耽误了正规抗痨治疗会贻误病情。最好还是在医生和药师的指导下用药。

03

误区三:频繁更换抗生素

抗生素的疗效有一个周期问题,如果使用某种抗生素的疗效暂时不好,首先应当考虑用药时间不足。此外,给药途径不当以及全身的免疫功能状态等因素也可影响抗生素的疗效。如果与这些因素有关,只要加以调整,疗效就会提高。

频繁更换药物,会造成用药混乱,从而伤害身体。况且,频繁换药很容易使细菌产生对多种药物的耐药性。

04

误区四:一旦有效就停药

前面我们知道,抗生素的使用有一个周期。用药时间不足的话,有可能根本见不到效果;即便见了效,也应该在医生的指导下服够必须的周期。如果有了一点效果就停药的话,不但治不好病,即便已经好转的病情也可能因为残余细菌作怪而反弹。

05

误区五:抗生素=消炎药

抗生素不直接针对炎症发挥作用,而是针对引起炎症的微生物起到杀灭的作用。消炎药是针对炎症的,比如常用的阿司匹林等消炎镇痛药。

多数人误以为抗生素可以治疗一切炎症。实际上抗生素仅适用于由细菌引起的炎症,而对由病毒引起的炎症无效。人体内存在大量正常有益的菌群,如果用抗生素治疗无菌性炎症,这些药物进入人体内后将会压抑和杀灭人体内有益的菌群,引起菌群失调,造成抵抗力下降。日常生活中经常发生的局部软组织的淤血、红肿、疼痛、过敏反应引起的接触性皮炎、药物性皮炎以及病毒引起的炎症等,都不宜使用抗生素来进行治疗。

06

误区六:抗生素可预防感染

抗生素仅适用于由细菌和部分其他微生物引起的炎症,抗生素是针对引起炎症的微生物,是杀灭微生物的。没有预防感染的作用,相反,长期使用抗生素会引起细菌耐药。

07

误区七:抗生素联合治疗

一般来说不提倡联合使用抗生素。因为联合用药可以增加一些不合理的用药因素,这样不仅不能增加疗效,反而降低疗效,而且容易产生一些毒副作用、或者细菌对药物的耐药性。所以合并用药的种类越多,由此引起的毒副作用、不良反应发生率就越高。一般来说,为避免耐药和毒副作用的产生,能用一种抗生素解决的问题绝不应使用两种。

08

误区八:抗生素越贵越好

其实每种抗生素都有自身的特性,优势劣势各不相同。一般要因病、因人选择,坚持个体化给药。例如,红霉素是老牌抗生素,价格很便宜,它对于军团菌和支原体感染的肺炎具有相当好的疗效,而价格非常高的碳青霉烯类的抗生素和三代头孢菌素对付这些病就不如红霉素。而且,有的老药药效比较稳定,价格便宜,不良反应较明确。

另一方面,新的抗生素的诞生往往是因为老的抗生素发生了耐药,如果老的抗生素有疗效,应当使用老的抗生素。

09

误区九:家庭药箱常备抗生素

一种抗生素不能包治百病,你这次得病这种抗生素有效,下次得病这种抗生素未必就有效。因此,针对不同的感染需要使用不同的抗生素,而这些知识必须是受过专业培训的医生和药师才能掌握,普通患者自己随意使用抗生素不仅难以对症下药,容易耽误病情,而且还会增加抗生素耐药的机会。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1308810, encodeId=e139130881082, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jun 21 09:28:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213221, encodeId=abb221322139, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jun 20 20:38:56 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213177, encodeId=49782131e74d, content=签到学习了…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Jun 20 19:11:46 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213040, encodeId=8a9a2130402e, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Tue Jun 20 08:26:38 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212984, encodeId=0a84212984a7, content=学习了,分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Tue Jun 20 06:45:17 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212952, encodeId=1ec6212952c9, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Jun 20 06:07:03 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212935, encodeId=61d721293549, content=抗生素的科学使用是个大问题。, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCxzIqGgHGpnv0v7a7MZQHVVjxvBfHWenpTPmFhDxa6vn3qno88vft2DRqYcyUBQFCRouANp2WgxQ/0, createdBy=b35a44222, createdName=kane35, createdTime=Tue Jun 20 03:04:16 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212915, encodeId=5b2e212915ac, content=很好的指导用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jun 20 00:18:59 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212830, encodeId=2275212830cd, content=确实是这样…, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4aca1635970, createdName=一露鹤笙, createdTime=Mon Jun 19 19:52:03 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212827, encodeId=0b2b21282ebf, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jun 19 19:35:44 CST 2017, time=2017-06-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1308810, encodeId=e139130881082, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jun 21 09:28:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213221, encodeId=abb221322139, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jun 20 20:38:56 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213177, encodeId=49782131e74d, content=签到学习了…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Jun 20 19:11:46 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213040, encodeId=8a9a2130402e, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Tue Jun 20 08:26:38 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212984, encodeId=0a84212984a7, content=学习了,分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Tue Jun 20 06:45:17 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212952, encodeId=1ec6212952c9, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Jun 20 06:07:03 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212935, encodeId=61d721293549, content=抗生素的科学使用是个大问题。, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCxzIqGgHGpnv0v7a7MZQHVVjxvBfHWenpTPmFhDxa6vn3qno88vft2DRqYcyUBQFCRouANp2WgxQ/0, createdBy=b35a44222, createdName=kane35, createdTime=Tue Jun 20 03:04:16 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212915, encodeId=5b2e212915ac, content=很好的指导用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jun 20 00:18:59 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212830, encodeId=2275212830cd, content=确实是这样…, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4aca1635970, createdName=一露鹤笙, createdTime=Mon Jun 19 19:52:03 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212827, encodeId=0b2b21282ebf, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jun 19 19:35:44 CST 2017, time=2017-06-19, status=1, ipAttribution=)]
    2017-06-20 wxl882001

    学习一下

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1308810, encodeId=e139130881082, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jun 21 09:28:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213221, encodeId=abb221322139, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jun 20 20:38:56 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213177, encodeId=49782131e74d, content=签到学习了…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Jun 20 19:11:46 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213040, encodeId=8a9a2130402e, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Tue Jun 20 08:26:38 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212984, encodeId=0a84212984a7, content=学习了,分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Tue Jun 20 06:45:17 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212952, encodeId=1ec6212952c9, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Jun 20 06:07:03 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212935, encodeId=61d721293549, content=抗生素的科学使用是个大问题。, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCxzIqGgHGpnv0v7a7MZQHVVjxvBfHWenpTPmFhDxa6vn3qno88vft2DRqYcyUBQFCRouANp2WgxQ/0, createdBy=b35a44222, createdName=kane35, createdTime=Tue Jun 20 03:04:16 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212915, encodeId=5b2e212915ac, content=很好的指导用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jun 20 00:18:59 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212830, encodeId=2275212830cd, content=确实是这样…, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4aca1635970, createdName=一露鹤笙, createdTime=Mon Jun 19 19:52:03 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212827, encodeId=0b2b21282ebf, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jun 19 19:35:44 CST 2017, time=2017-06-19, status=1, ipAttribution=)]
    2017-06-20 杨柳青青

    签到学习了…………

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1308810, encodeId=e139130881082, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jun 21 09:28:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213221, encodeId=abb221322139, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jun 20 20:38:56 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213177, encodeId=49782131e74d, content=签到学习了…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Jun 20 19:11:46 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213040, encodeId=8a9a2130402e, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Tue Jun 20 08:26:38 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212984, encodeId=0a84212984a7, content=学习了,分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Tue Jun 20 06:45:17 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212952, encodeId=1ec6212952c9, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Jun 20 06:07:03 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212935, encodeId=61d721293549, content=抗生素的科学使用是个大问题。, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCxzIqGgHGpnv0v7a7MZQHVVjxvBfHWenpTPmFhDxa6vn3qno88vft2DRqYcyUBQFCRouANp2WgxQ/0, createdBy=b35a44222, createdName=kane35, createdTime=Tue Jun 20 03:04:16 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212915, encodeId=5b2e212915ac, content=很好的指导用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jun 20 00:18:59 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212830, encodeId=2275212830cd, content=确实是这样…, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4aca1635970, createdName=一露鹤笙, createdTime=Mon Jun 19 19:52:03 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212827, encodeId=0b2b21282ebf, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jun 19 19:35:44 CST 2017, time=2017-06-19, status=1, ipAttribution=)]
    2017-06-20 130****4638

    学习了谢谢分享。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1308810, encodeId=e139130881082, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jun 21 09:28:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213221, encodeId=abb221322139, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jun 20 20:38:56 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213177, encodeId=49782131e74d, content=签到学习了…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Jun 20 19:11:46 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213040, encodeId=8a9a2130402e, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Tue Jun 20 08:26:38 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212984, encodeId=0a84212984a7, content=学习了,分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Tue Jun 20 06:45:17 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212952, encodeId=1ec6212952c9, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Jun 20 06:07:03 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212935, encodeId=61d721293549, content=抗生素的科学使用是个大问题。, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCxzIqGgHGpnv0v7a7MZQHVVjxvBfHWenpTPmFhDxa6vn3qno88vft2DRqYcyUBQFCRouANp2WgxQ/0, createdBy=b35a44222, createdName=kane35, createdTime=Tue Jun 20 03:04:16 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212915, encodeId=5b2e212915ac, content=很好的指导用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jun 20 00:18:59 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212830, encodeId=2275212830cd, content=确实是这样…, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4aca1635970, createdName=一露鹤笙, createdTime=Mon Jun 19 19:52:03 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212827, encodeId=0b2b21282ebf, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jun 19 19:35:44 CST 2017, time=2017-06-19, status=1, ipAttribution=)]
    2017-06-20 杨利洪

    学习了,分享了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1308810, encodeId=e139130881082, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jun 21 09:28:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213221, encodeId=abb221322139, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jun 20 20:38:56 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213177, encodeId=49782131e74d, content=签到学习了…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Jun 20 19:11:46 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213040, encodeId=8a9a2130402e, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Tue Jun 20 08:26:38 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212984, encodeId=0a84212984a7, content=学习了,分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Tue Jun 20 06:45:17 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212952, encodeId=1ec6212952c9, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Jun 20 06:07:03 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212935, encodeId=61d721293549, content=抗生素的科学使用是个大问题。, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCxzIqGgHGpnv0v7a7MZQHVVjxvBfHWenpTPmFhDxa6vn3qno88vft2DRqYcyUBQFCRouANp2WgxQ/0, createdBy=b35a44222, createdName=kane35, createdTime=Tue Jun 20 03:04:16 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212915, encodeId=5b2e212915ac, content=很好的指导用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jun 20 00:18:59 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212830, encodeId=2275212830cd, content=确实是这样…, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4aca1635970, createdName=一露鹤笙, createdTime=Mon Jun 19 19:52:03 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212827, encodeId=0b2b21282ebf, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jun 19 19:35:44 CST 2017, time=2017-06-19, status=1, ipAttribution=)]
    2017-06-20 惠映实验室

    学习了,谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1308810, encodeId=e139130881082, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jun 21 09:28:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213221, encodeId=abb221322139, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jun 20 20:38:56 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213177, encodeId=49782131e74d, content=签到学习了…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Jun 20 19:11:46 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213040, encodeId=8a9a2130402e, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Tue Jun 20 08:26:38 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212984, encodeId=0a84212984a7, content=学习了,分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Tue Jun 20 06:45:17 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212952, encodeId=1ec6212952c9, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Jun 20 06:07:03 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212935, encodeId=61d721293549, content=抗生素的科学使用是个大问题。, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCxzIqGgHGpnv0v7a7MZQHVVjxvBfHWenpTPmFhDxa6vn3qno88vft2DRqYcyUBQFCRouANp2WgxQ/0, createdBy=b35a44222, createdName=kane35, createdTime=Tue Jun 20 03:04:16 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212915, encodeId=5b2e212915ac, content=很好的指导用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jun 20 00:18:59 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212830, encodeId=2275212830cd, content=确实是这样…, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4aca1635970, createdName=一露鹤笙, createdTime=Mon Jun 19 19:52:03 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212827, encodeId=0b2b21282ebf, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jun 19 19:35:44 CST 2017, time=2017-06-19, status=1, ipAttribution=)]
    2017-06-20 kane35

    抗生素的科学使用是个大问题。

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1308810, encodeId=e139130881082, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jun 21 09:28:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213221, encodeId=abb221322139, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jun 20 20:38:56 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213177, encodeId=49782131e74d, content=签到学习了…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Jun 20 19:11:46 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213040, encodeId=8a9a2130402e, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Tue Jun 20 08:26:38 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212984, encodeId=0a84212984a7, content=学习了,分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Tue Jun 20 06:45:17 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212952, encodeId=1ec6212952c9, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Jun 20 06:07:03 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212935, encodeId=61d721293549, content=抗生素的科学使用是个大问题。, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCxzIqGgHGpnv0v7a7MZQHVVjxvBfHWenpTPmFhDxa6vn3qno88vft2DRqYcyUBQFCRouANp2WgxQ/0, createdBy=b35a44222, createdName=kane35, createdTime=Tue Jun 20 03:04:16 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212915, encodeId=5b2e212915ac, content=很好的指导用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jun 20 00:18:59 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212830, encodeId=2275212830cd, content=确实是这样…, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4aca1635970, createdName=一露鹤笙, createdTime=Mon Jun 19 19:52:03 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212827, encodeId=0b2b21282ebf, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jun 19 19:35:44 CST 2017, time=2017-06-19, status=1, ipAttribution=)]
    2017-06-20 Y—xianghai

    很好的指导用药

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1308810, encodeId=e139130881082, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jun 21 09:28:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213221, encodeId=abb221322139, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jun 20 20:38:56 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213177, encodeId=49782131e74d, content=签到学习了…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Jun 20 19:11:46 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213040, encodeId=8a9a2130402e, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Tue Jun 20 08:26:38 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212984, encodeId=0a84212984a7, content=学习了,分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Tue Jun 20 06:45:17 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212952, encodeId=1ec6212952c9, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Jun 20 06:07:03 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212935, encodeId=61d721293549, content=抗生素的科学使用是个大问题。, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCxzIqGgHGpnv0v7a7MZQHVVjxvBfHWenpTPmFhDxa6vn3qno88vft2DRqYcyUBQFCRouANp2WgxQ/0, createdBy=b35a44222, createdName=kane35, createdTime=Tue Jun 20 03:04:16 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212915, encodeId=5b2e212915ac, content=很好的指导用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jun 20 00:18:59 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212830, encodeId=2275212830cd, content=确实是这样…, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4aca1635970, createdName=一露鹤笙, createdTime=Mon Jun 19 19:52:03 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212827, encodeId=0b2b21282ebf, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jun 19 19:35:44 CST 2017, time=2017-06-19, status=1, ipAttribution=)]
    2017-06-19 一露鹤笙

    确实是这样…

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1308810, encodeId=e139130881082, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jun 21 09:28:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213221, encodeId=abb221322139, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Jun 20 20:38:56 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213177, encodeId=49782131e74d, content=签到学习了…………, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Jun 20 19:11:46 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213040, encodeId=8a9a2130402e, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Tue Jun 20 08:26:38 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212984, encodeId=0a84212984a7, content=学习了,分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Tue Jun 20 06:45:17 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212952, encodeId=1ec6212952c9, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Jun 20 06:07:03 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212935, encodeId=61d721293549, content=抗生素的科学使用是个大问题。, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCxzIqGgHGpnv0v7a7MZQHVVjxvBfHWenpTPmFhDxa6vn3qno88vft2DRqYcyUBQFCRouANp2WgxQ/0, createdBy=b35a44222, createdName=kane35, createdTime=Tue Jun 20 03:04:16 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212915, encodeId=5b2e212915ac, content=很好的指导用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Tue Jun 20 00:18:59 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212830, encodeId=2275212830cd, content=确实是这样…, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4aca1635970, createdName=一露鹤笙, createdTime=Mon Jun 19 19:52:03 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=212827, encodeId=0b2b21282ebf, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Mon Jun 19 19:35:44 CST 2017, time=2017-06-19, status=1, ipAttribution=)]
    2017-06-19 131****1460

    学习了受益匪浅。

    0

相关资讯

并非危言耸听,抗生素耐药性可能导致现代医学的终结

“世界正走向一个后抗生素时代,在这个时代,普通的感染可能会再次致命。如果目前的趋势继续下去,复杂的医疗干预措施,如器官移植、关节置换、癌症化疗和照顾早产儿,将会变得十分困难危险。这甚至可能导致现代医学的终结。”

Heart:预防性抗生素的使用真的能改善感染性心内膜炎的预后吗?

对于感染性心内膜炎患者的抗生素预防性使用(AP)一直存在争议。近日,在国际心血管权威杂志《Heart》上发表了一篇关于评估预防性抗生素的使用在细菌感染的预防或接受牙科手术的感染性心内膜炎患者中价值的荟萃分析。

穿拖鞋、浓眼影、爱粉红……这名个性教授有望解决超级细菌难题

Janelle Ayres教授是美国最著名的生物研究所之一Salk Institute for Biological Studies(以下简称Salk Institute)的一位科学家。几年前,她父亲因为感染超级细菌引发脓毒症,她守在床边度过整整9天痛苦的日子。父亲最终没有击败超级细菌,使她感到悲伤,继而感到沮丧。从那时起,她一直努力寻找一种更好的方法,来帮助跟父亲一样的不幸患者。

Nature:科学家发明“分子诱饵”,不用抗生素也能除掉细菌

抗生素耐药性问题是当今全球卫生面临的最大威胁之一。老牌抗生素耐药率不断升高,而近30年来又没有新的抗生素被发现或合成。这意味着,我们最终可能没有抗生素能对抗不断出现的耐药菌。因此,除了抗生素,科学家们也在努力寻找其他的抗菌方法。近日,华盛顿大学医学院的一项研究发现,一种分子诱饵可以靶向作用于肠道中能引起尿路感染的大肠杆菌,减少致病菌的同时不影响其他微生物组成。该研究发表于6月14日的Nature期

Nat Commun:部分病菌耐药基因与抗生素同出一源

抗生素滥用导致耐药病菌出现并广泛传播,使这些病菌获得耐药能力的基因从何而来?丹麦研究人员首次证实了科学界一个长久以来的猜想:向病菌提供耐药基因的,正是生产抗生素的细菌。

Crit Care Med:呼吸机械通气患者是否需要使用抗生素治疗?

近期,一项发表在杂志Crit Care Med上的研究旨在评估表现为吸入性细菌性肺炎或非细菌性吸入性肺炎症状的ICU昏迷患者中记录的细菌吸入性肺炎患者的比例。此项研究为前瞻性观察研究,选取250名昏迷(格拉斯哥昏迷量表评分≤8)并使用侵入性机械通气治疗的ICU患者。此项研究的主要结果是微生物学记录的细菌吸入性肺炎患者的比例。满足预期吸入综合征标准的患者在开始概率性抗生素治疗之前,常规地在支气管镜检